These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 36528918)

  • 1. Targeting cancer drug resistance utilizing organoid technology.
    Chai C; Ji P; Xu H; Tang H; Wang Z; Zhang H; Zhou W
    Biomed Pharmacother; 2023 Feb; 158():114098. PubMed ID: 36528918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.
    Li Q; Sun H; Luo D; Gan L; Mo S; Dai W; Liang L; Yang Y; Xu M; Li J; Zheng P; Li X; Li Y; Wang Z
    J Exp Clin Cancer Res; 2021 Nov; 40(1):348. PubMed ID: 34740372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell.
    Ukai S; Honma R; Sakamoto N; Yamamoto Y; Pham QT; Harada K; Takashima T; Taniyama D; Asai R; Fukada K; Naka K; Tanabe K; Ohdan H; Yasui W
    Oncogene; 2020 Dec; 39(50):7265-7278. PubMed ID: 33046798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
    Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
    Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer research using organoid technology.
    Kretzschmar K
    J Mol Med (Berl); 2021 Apr; 99(4):501-515. PubMed ID: 33057820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphere‑forming assay vs. organoid culture: Determining long‑term stemness and the chemoresistant capacity of primary colorectal cancer cells.
    Zhao H; Yan C; Hu Y; Mu L; Huang K; Li Q; Li X; Tao D; Qin J
    Int J Oncol; 2019 Mar; 54(3):893-904. PubMed ID: 30664193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.
    Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W
    Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
    Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
    Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and perspective of organoid technology in cancer-related translational medicine.
    Lin Y; Jiang L; He Q; Yuan M; Cao J
    Biomed Pharmacother; 2022 May; 149():112869. PubMed ID: 35358798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organoid technology in cancer precision medicine.
    Xia X; Li F; He J; Aji R; Gao D
    Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.
    Wang Z; Chen W; Zuo L; Xu M; Wu Y; Huang J; Zhang X; Li Y; Wang J; Chen J; Wang H; Sun H
    Cancer Commun (Lond); 2022 Mar; 42(3):245-265. PubMed ID: 35234370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
    Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
    Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational models of 3-D organoids and cancer stem cells in gastric cancer research.
    Wuputra K; Ku CC; Kato K; Wu DC; Saito S; Yokoyama KK
    Stem Cell Res Ther; 2021 Sep; 12(1):492. PubMed ID: 34488885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical approaches to targeting drug resistance in cancer stem cells.
    Sotiropoulou PA; Christodoulou MS; Silvani A; Herold-Mende C; Passarella D
    Drug Discov Today; 2014 Oct; 19(10):1547-62. PubMed ID: 24819719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma.
    Sundar SJ; Shakya S; Barnett A; Wallace LC; Jeon H; Sloan A; Recinos V; Hubert CG
    Transl Oncol; 2022 Jan; 15(1):101251. PubMed ID: 34700192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organoid technology and applications in cancer research.
    Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
    J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
    Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
    J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.